Advertiser Disclosure: BestMedsHub may earn a commission when readers sign up with telehealth providers linked on this page. Editorial recommendations are independent. This article is informational only and is not a substitute for personalized care from a licensed clinician.

Ro vs Hims for ED in 2026: All 4 SKU Pairs Compared, Side by Side

Last updated: May 18, 2026 · Medically reviewed by Dr. Marcus Tan, MD · ~11 min read

The 60-second answer. For pure cash price, Hims is cheaper than Ro across generic sildenafil entry plans, daily 5 mg tadalafil (about $45 vs $66 per month), the compounded sil-plus-tad sublingual combo (Hard Mints ~$6 to $7.50 vs Ro Sparks ~$12 per dose), and the daily compounded chewable. Ro wins on pharma-partnership credibility: as of June 2025 Novo Nordisk dropped Hims as a Wegovy partner but kept Ro, and Eli Lilly chose Ro for direct branded Zepbound vial distribution. For most ED-only shoppers Hims has the price edge; for shoppers who value pharma-partnership signaling, Ro has the credibility edge.

How we compared Ro and Hims for ED in 2026

Both Ro and Hims publish their own “Ro vs Hims” comparison pages. Neither is neutral. Ro’s page emphasizes Sparks and branded Cialis. The Hims page emphasizes Hard Mints pricing. Neither stacks all four head-to-head SKU pairs side by side with refresh-dated price math, which is what shoppers actually need.

This guide does. We walk through the four SKU pairs that map directly between the two brands’ lineups in 2026: (1) generic sildenafil 50 mg as-needed, (2) generic tadalafil daily 5 mg, (3) the compounded sublingual sil-plus-tad combo (Ro Sparks vs Hims Hard Mints), and (4) the daily compounded chewable/gummy (Ro Daily Rise Gummies vs the Hims daily ED chewable). All prices were verified in May 2026 on each brand’s pricing page; both adjust pricing quarterly, so reverify before purchase.

SKU pair 1 — Generic sildenafil 50 mg as-needed

This is the workhorse SKU for both brands and the closest thing to apples-to-apples. Both platforms ship FDA-approved generic sildenafil from licensed US pharmacies, both require an async intake, and both run on auto-renewing subscriptions.

$/dose verdict (sildenafil 50 mg): Functional tie. Both bottom out around $2 to $4 per dose on multi-month plans, and the actual delta you will see depends more on the promo you land than on which brand you pick. For absolute lowest cash price on sildenafil, neither beats GoodRx at a brick-and-mortar pharmacy, which can hit roughly $0.50 to $1 per dose on 30-count generic sildenafil. Both Ro and Hims sell convenience and the no-PCP-visit script; not the pill itself.

[provider=”ro”]

SKU pair 2 — Generic tadalafil daily 5 mg

The daily 5 mg tadalafil protocol is the highest-LTV product for both brands because it ships 30 doses per month on autopilot. It is also where the price gap between Ro and Hims is the most measurable.

$/dose verdict (daily tadalafil): Hims is roughly 32 percent cheaper per year on the same FDA-approved generic — about $252 in annual savings versus Ro on identical molecules. If daily tadalafil is your protocol and price is your priority, Hims wins this matchup decisively. The trade-off: Ro’s daily tadalafil page is bundled with broader men’s-health add-ons (Roman Swipes for PE, hair-loss, etc.), which some readers value.

SKU pair 3 — Compounded sublingual combo: Ro Sparks vs Hims Hard Mints

This is the SKU pair where the price gap is widest and where both companies most aggressively market a “premium” experience. Important: Ro Sparks and Hims Hard Mints are both compounded by 503A pharmacies and are NOT FDA-approved as finished products. The active ingredients (sildenafil and tadalafil) are FDA-approved separately, but the combo dosage form is a compounded preparation that the FDA has not reviewed for safety or efficacy as a finished medication.

$/dose verdict (compounded sublingual): Hims Hard Mints undercut Ro Sparks by roughly 40 to 50 percent for the same active ingredients in the same compounded category. On a 10-dose-per-month protocol that is about $540 to $720 in annual savings. We cover this matchup in depth in our Ro Sparks vs Hims Hard Mints guide. If you specifically want a sublingual combo and price matters, Hims is the math-driven pick. If you trust the Ro brand and packaging more, Ro Sparks is the premium pick.

[provider=”hims”]

SKU pair 4 — Daily compounded ED: Ro Daily Rise Gummies vs Hims daily chewable

Both brands shipped a daily compounded tadalafil product in 2024-2025 to capture pill-averse customers. Both are compounded 503A preparations and not FDA-approved as finished products. The Ro Daily Rise Gummies use 7 mg tadalafil per gummy, which is higher than the FDA-approved daily Cialis doses of 2.5 mg and 5 mg — that dosage is only possible because the product is compounded.

$/dose verdict (daily compounded): Hims is cheaper per month, but Ro’s gummy format is genuinely unique on the market and serves customers who actively refuse to swallow pills. If you would equally accept a chewable, Hims wins on price. If you want a gummy specifically, Ro Daily Rise is the only mainstream option.

Visit and prescription experience compared

Both Ro and Hims use an async-first telehealth model: you complete a branching intake questionnaire, a licensed provider reviews it asynchronously (no video unless your state requires it or the provider needs clarification), and an Rx is issued or declined. Both are licensed across all 50 states plus DC.

• Speed to first script: Ro typically reviews within 24 hours; Hims similar. Real-world Trustpilot reports show both brands occasionally taking 48 to 72 hours during peak demand. Plan for 3 to 5 business days from intake to your pills landing on your doorstep.
• Refill cadence: Both default to monthly auto-ship with the option to switch to quarterly. Quarterly plans on both brands save roughly 10 to 15 percent per dose.
• Provider messaging: Ro offers free unlimited provider messaging after the initial visit. Hims offers messaging through its care team interface; functionally similar.
• Clinician model: Out-of-Pocket’s deep dive on Ro reports that about 70 percent of Ro’s clinician network is W-2 salaried and compensated on satisfaction and outcomes (not Rx volume) — uncommon in telehealth. Hims uses a mix of W-2 and 1099 contracted providers and does not disclose the ratio publicly.
• What disqualifies you on both: Active nitrate use, riociguat, recent MI or stroke (typically last 6 months), unstable angina, severe hypotension or hypertension, severe hepatic impairment. Men over 65 with cardiac history are often redirected to a sync visit or declined.

Net: the patient experience is functionally similar between the two. The async model means you should expect to receive your script without a phone call in most states.

Trust and reputation compared

This is where the two brands diverge most clearly.

Verdict on trust: Hims wins on financial transparency (audited 10-K reporting makes their pricing, gross margin, and customer retention numbers public) and on Trustpilot aggregate. Both brands have nearly identical BBB customer-review averages around 1.2 to 1.3, with cancellation friction the dominant complaint pattern on both. Translation: BBB collects unhappy customers, Trustpilot collects everyone. Both are imperfect signals, but Hims comes out marginally ahead by both metrics.

For deeper trust analysis on Ro specifically, see our Roman ED Review 2026.

Pharma partnership credibility — the most overlooked tiebreaker

This is the single signal where Ro decisively wins, and it has nothing to do with ED products. It has to do with which telehealth platform Big Pharma chooses to trust.

• December 2024: Eli Lilly signed a direct distribution deal with Ro for branded Zepbound vials (tirzepatide for weight loss), 2.5 mg at $399/mo and 5 mg at $549/mo. Lilly did not extend the same deal to Hims.
• June 2025: Novo Nordisk ended its Wegovy (semaglutide) partnership with Hims & Hers Health but kept its deals with Ro and LifeMD. Branded Wegovy continues at $499/mo via Ro. This was a publicly reported breakup; Hims stock dipped on the news.
• What this signals: When two of the largest pharma companies in the world ran due-diligence on telehealth partners in 2024-2025, both kept Ro and one actively dropped Hims. That is a strong third-party trust signal that no marketing copy can manufacture.

For ED-only shoppers this matters less directly (neither Ro nor Hims sells branded Viagra exclusively, and both sell FDA-approved generics from the same supplier ecosystem). But if you care about which platform Big Pharma trusts with brand-name distribution, Ro is the answer in 2026.

Who should pick Ro, who should pick Hims (use-case segmentation)

Pick Ro if:

• You want access to branded Viagra (Pfizer) or branded Cialis (Lilly) at clinical pricing — Ro is one of very few telehealth players carrying both.
• You specifically want a daily ED gummy (Daily Rise) and not a chewable or pill.
• You value the pharma-partnership signal (Lilly Zepbound, Novo Wegovy retained).
• You want the highest probability that your prescribing clinician is a W-2 employee compensated on outcomes, not Rx volume.
• You are willing to pay a ~40 to 50 percent premium on the compounded sublingual combo (Ro Sparks at $12/dose vs Hims Hard Mints at ~$7/dose) for Ro’s brand.

Pick Hims if:

• Price is your primary filter. Hims is cheaper on 3 of the 4 SKU pairs (sildenafil tied, daily tadalafil, compounded combo, daily chewable).
• You want a publicly traded company with audited financials so you can read the 10-K.
• You want the highest Trustpilot aggregate (~4.1/5 vs Ro’s ~3.7-3.8/5).
• You want the compounded sublingual combo at the lowest verifiable price (Hard Mints at ~$6 to $7.50/dose).
• You want the daily ED chewable format and want to pay roughly $20 to $30 less per month than Ro Daily Rise.

Pick neither if: you are a low-volume user who can pay cash at a local pharmacy. Generic sildenafil 30-count is roughly $30 at Costco with a GoodRx coupon, or about $3.60 at Mark Cuban’s Cost Plus Drugs. Both Ro and Hims sell you the script and convenience; the pill itself is commodified. See our full Best Online ED Treatment 2026 guide for a use-case-segmented breakdown across all major platforms, and our ED treatment hub for clinical background.

[provider=”ro”]

[provider=”hims”]

Frequently Asked Questions

Sources

• Ro pricing page (verified May 2026)
• Ro ED product hub (verified May 2026)
• Ro Sparks product page (verified May 2026)
• Ro Daily Rise Gummies product page (verified May 2026)
• Hims men’s health (verified May 2026)
• Hims ED hub (verified May 2026)
• Trustpilot — Ro (verified May 2026)
• Trustpilot — Hims (verified May 2026)
• BBB profile — Ro
• BBB profile — Hims & Hers Health
• STAT News — Eli Lilly Zepbound deal with Ro (Dec 2024)
• Healthcare Brew — Novo Nordisk ends Hims Wegovy partnership (June 2025)
• Hims & Hers Health SEC filings (NYSE: HIMS 10-K)
• Sacra — Ro revenue analysis ($598M 2024)
• Out-of-Pocket — Ro deep dive (clinician model)
• FDA — sildenafil approval record
• FDA — tadalafil approval record
• FDA — Drug compounding 503A overview

Medical disclaimer: Information here is educational only. ED can be a symptom of underlying cardiovascular, endocrine, or psychological conditions including diabetes, hypertension, depression, or low testosterone. Do not start any PDE5 inhibitor (sildenafil, tadalafil, vardenafil) without a licensed clinician’s review, especially if you take nitrates, riociguat, or alpha-blockers, or if you have a history of MI, stroke, unstable angina, severe hypotension, or severe hepatic impairment. Compounded medications (Ro Sparks, Hims Hard Mints, Ro Daily Rise Gummies, Hims daily ED chewable) are not FDA-approved as finished products.